Literature DB >> 9780151

Therapy with monoclonal antibodies. II. The contribution of Fc gamma receptor binding and the influence of C(H)1 and C(H)3 domains on in vivo effector function.

J D Isaacs1, J Greenwood, H Waldmann.   

Abstract

An in vivo model is used to define Fc motifs engaged by mAbs to deplete target cells. Human IgG1 and human IgG4 were very potent, and mutations within a motif critical for Fc gammaR binding (glutamate 233 to proline, leucine/phenylalanine 234 to valine, and leucine 235 to alanine) completely prevented depletion. Mouse IgG2b was also potent, and mutations to prevent complement activation did not impair depletion with this isotype, as previously shown for human IgG1. In contrast, a mutation that impaired binding to mouse Fc gammaRII (glutamate 318 to alanine) eliminated effector function of mouse IgG2b and also reduced the potency of human IgG4. To reveal potential contributions of domains other than C(H)2, domain switch mutants were created between human IgG1 and rat IgG2a. Two hybrid mAbs were generated with potencies exceeding anything previously seen in this model. While their mechanism of depletion was not defined, their activity appeared dependent upon interdomain interactions in the Fc region.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9780151

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  15 in total

Review 1.  Immunomodulation of autoimmune responses with monoclonal antibodies and immunoadhesins: treatment of ocular inflammatory disease in the next millennium.

Authors:  A D Dick; J D Isaacs
Journal:  Br J Ophthalmol       Date:  1999-11       Impact factor: 4.638

2.  Effector differentiation is not prerequisite for generation of memory cytotoxic T lymphocytes.

Authors:  N Manjunath; P Shankar; J Wan; W Weninger; M A Crowley; K Hieshima; T A Springer; X Fan; H Shen; J Lieberman; U H von Andrian
Journal:  J Clin Invest       Date:  2001-09       Impact factor: 14.808

3.  Fn14-TRAIL, a chimeric intercellular signal exchanger, attenuates experimental autoimmune encephalomyelitis.

Authors:  Marjaneh Razmara; Brendan Hilliard; Azadeh K Ziarani; Ramachandran Murali; Srikanth Yellayi; Mustafa Ghazanfar; Youhai H Chen; Mark L Tykocinski
Journal:  Am J Pathol       Date:  2009-01-15       Impact factor: 4.307

4.  Chimeric antigen receptors with mutated IgG4 Fc spacer avoid fc receptor binding and improve T cell persistence and antitumor efficacy.

Authors:  Mahesh Jonnalagadda; Armen Mardiros; Ryan Urak; Xiuli Wang; Lauren J Hoffman; Alyssa Bernanke; Wen-Chung Chang; William Bretzlaff; Renate Starr; Saul Priceman; Julie R Ostberg; Stephen J Forman; Christine E Brown
Journal:  Mol Ther       Date:  2014-11-04       Impact factor: 11.454

5.  Phase I trial of a novel anti-GD2 monoclonal antibody, Hu14.18K322A, designed to decrease toxicity in children with refractory or recurrent neuroblastoma.

Authors:  Fariba Navid; Paul M Sondel; Raymond Barfield; Barry L Shulkin; Robert A Kaufman; Jim A Allay; Jacek Gan; Paul Hutson; Songwon Seo; Kyungmann Kim; Jacob Goldberg; Jacquelyn A Hank; Catherine A Billups; Jianrong Wu; Wayne L Furman; Lisa M McGregor; Mario Otto; Stephen D Gillies; Rupert Handgretinger; Victor M Santana
Journal:  J Clin Oncol       Date:  2014-04-07       Impact factor: 44.544

6.  Fcgamma receptor-dependent effector mechanisms regulate CD19 and CD20 antibody immunotherapies for B lymphocyte malignancies and autoimmunity.

Authors:  Thomas F Tedder; Aris Baras; Yan Xiu
Journal:  Springer Semin Immunopathol       Date:  2006-11-08

Review 7.  Antibody engineering to develop new antirheumatic therapies.

Authors:  John D Isaacs
Journal:  Arthritis Res Ther       Date:  2009-05-19       Impact factor: 5.156

Review 8.  Influence of immunoglobulin isotype on therapeutic antibody function.

Authors:  Stephen A Beers; Martin J Glennie; Ann L White
Journal:  Blood       Date:  2016-01-13       Impact factor: 22.113

9.  Type-I interferon is critical for FasL expression on lung cells to determine the severity of influenza.

Authors:  Daisuke Fujikura; Satoko Chiba; Daisuke Muramatsu; Mika Kazumata; Yosuke Nakayama; Taro Kawai; Shizuo Akira; Hiroshi Kida; Tadaaki Miyazaki
Journal:  PLoS One       Date:  2013-02-08       Impact factor: 3.240

10.  The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy.

Authors:  Junji Uchida; Yasuhito Hamaguchi; Julie A Oliver; Jeffrey V Ravetch; Jonathan C Poe; Karen M Haas; Thomas F Tedder
Journal:  J Exp Med       Date:  2004-06-21       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.